Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
8G2dbP74bLF6ESfp
